NeuroMetrix, Inc. (NURO)

NASDAQ: NURO · IEX Real-Time Price · USD
1.47
+0.02 (1.64%)
At close: Mar 31, 2023, 3:58 PM
1.50
+0.03 (2.39%)
After-hours: Mar 31, 2023, 4:10 PM EDT
1.64%
Market Cap 11.38M
Revenue (ttm) 8.26M
Net Income (ttm) -4.42M
Shares Out 7.79M
EPS (ttm) -0.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 20,141
Open 1.44
Previous Close 1.44
Day's Range 1.42 - 1.48
52-Week Range 1.33 - 5.89
Beta 2.31
Analysts Buy
Price Target n/a
Earnings Date Apr 25, 2023

About NURO

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1996
Employees 23
Stock Exchange NASDAQ
Ticker Symbol NURO
Full Company Profile

Financial Performance

In 2022, NeuroMetrix's revenue was $8.26 million, an increase of 0.03% compared to the previous year's $8.25 million. Losses were -$4.42 million, 93.6% more than in 2021.

Financial Statements

News

NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting

WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in Ft. ...

1 week ago - GlobeNewsWire

NeuroMetrix Reports Q4 and Full Year 2022 Financial Results

WOBURN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2022. The Company's ...

1 month ago - GlobeNewsWire

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call

WOBURN, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 fourth quarter and year end financial results before the opening of th...

1 month ago - GlobeNewsWire

NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

Point-of-care technology helps healthcare providers rapidly identify at-risk patients Point-of-care technology helps healthcare providers rapidly identify at-risk patients

2 months ago - GlobeNewsWire

NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting

WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will introduce Quell Fibromyalgia at the American College of Rheumatology Annual Meeting, ACR Convergence 2022, on Nov...

5 months ago - GlobeNewsWire

NeuroMetrix Reports Q3 2022 Financial Results

WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and nine-month period ended September 30, 2022. The C...

5 months ago - GlobeNewsWire

NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call

WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 third quarter financial results before the opening of the market on Oc...

6 months ago - GlobeNewsWire

NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business

WOBURN, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Jonathan "Breck" Harmel as National Director of Sales, Neuromodulation. Mr. Har...

7 months ago - GlobeNewsWire

NeuroMetrix Reports Q2 2022 Financial Results

WOBURN, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and six months period ended June 30, 2022. The Compan...

9 months ago - GlobeNewsWire

NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call

WOBURN, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 second quarter financial results before the opening of the market on J...

9 months ago - GlobeNewsWire

NeuroMetrix Appoints Brad Fluegel to its Board of Directors

WOBURN, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the appointment of Bradley M. Fluegel to its Board of Directors, effective as of July 1, 2022.

9 months ago - GlobeNewsWire

6 Stocks Halted In Thursday's Session: Here's Why

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore and bri...

Other symbols: BGXXCLEUDPSIVEDU
11 months ago - Benzinga

Why Is NeuroMetrix (NURO) Stock Up 70% Today?

Today, investors in NeuroMetrix and NURO stock are cheering an announcement that the FDA has approved the company to market its Quell device. The post Why Is NeuroMetrix (NURO) Stock Up 70% Today?

11 months ago - InvestorPlace

Why NeuroMetrix Shares Are Skyrocketing

NeuroMetrix Inc (NASDAQ: NURO) shares are trading higher by 30.10% at $4.06 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid f...

11 months ago - Benzinga

NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation devic...

11 months ago - GlobeNewsWire

NeuroMetrix Reports Q1 2022 Financial Results

WOBURN, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2022. The Company's mission is to re...

1 year ago - GlobeNewsWire

NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference Call

WOBURN, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 first quarter financial results before the opening of the market on A...

1 year ago - GlobeNewsWire

NeuroMetrix's Quell Neuromodulator Will Be Tested In Long COVID-19 Syndrome

NeuroMetrix Inc's (NASDAQ: NURO) Quell wearable neuromodulation technology will be evaluated for fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID").  Q...

1 year ago - Benzinga

NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 Syndrome

WOBURN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell wearable neuromodulation technology will be evaluated for treatment of a fibromyalgia-l...

1 year ago - GlobeNewsWire

NeuroMetrix Reports Q4 and Full Year 2021 Financial Results

WOBURN, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2021. The Company's ...

1 year ago - GlobeNewsWire

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2021 Financial Results Conference Call

WOBURN, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 fourth quarter and full year financial results before the opening of t...

1 year ago - GlobeNewsWire

Neurometrix up 35% after receiving FDA Breakthrough Designation for its Quell tech

NeuroMetrix Inc. (NASDAQ: NURO) shot up 35% after announcing that the FDA awarded it Breakthrough Device Designation for its Quell technology. This innovative technology is designed to help reduce sev...

1 year ago - Invezz

NURO Stock: Why NeuroMetrix Investors Are Feeling No Pain Today

NeuroMetrix (NURO) stock is rocketing higher on Tuesday thanks to the FDA granting it Breakthrough Designation for one of its devices. The post NURO Stock: Why NeuroMetrix Investors Are Feeling No Pai...

1 year ago - InvestorPlace

NeuroMetrix Shares Rally On FDA Breakthrough Tag For Neurostimulation Device

The FDA has granted Breakthrough Designation to NeuroMetrix Inc's (NASDAQ:NURO) Quell technology for reducing moderate to severe symptoms of chemotherapy-induced peripheral neuropathy (CIPN) that have...

1 year ago - Benzinga

NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology

WOBURN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell® technology has received Breakthrough Designation from the U.S. Food and Drug Administr...

1 year ago - GlobeNewsWire